| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| S G Beck, S Birnstiel, K C Choi, W A Poulio. Fluoxetine selectively alters 5-hydroxytryptamine1A and gamma-aminobutyric acidB receptor-mediated hyperpolarization in area CA1, but not area CA3, hippocampal pyramidal cells. The Journal of pharmacology and experimental therapeutics. vol 281. issue 1. 1997-05-02. PMID:9103487. |
fluoxetine is a 5-hydroxytryptamine (5-ht, serotonin)-selective reuptake inhibitor (ssri) and is one of the main drugs used for the treatment of depression. |
1997-05-02 |
2023-08-12 |
rat |
| Y Clement, K H Kia, G Daval, D Verg. An autoradiographic study of serotonergic receptors in a murine genetic model of anxiety-related behaviors. Brain research. vol 709. issue 2. 1997-05-01. PMID:8833759. |
modifications in serotonin (5-ht) neurotransmission have been associated with the physiopathology of anxiety and depression. |
1997-05-01 |
2023-08-12 |
Not clear |
| A Duarte, H Mikkelsen, A Delini-Stul. Moclobemide versus fluoxetine for double depression: a randomized double-blind study. Journal of psychiatric research. vol 30. issue 6. 1997-04-29. PMID:9023788. |
the efficacy and tolerability of the selective reversible monoamine oxidase a inhibitor, moclobemide (300 mg/day) and the selective serotonin uptake inhibitor, fluoxetine (200 mg/day), were compared in a six-week single-centre double-blind fixed-dose study in patients (n = 42) with double depression (dsm-iii-r: dysthymia with superimposed major depressive episode) using weekly assessment on the hamilton depression rating scale (hdrs-17 items) and clinical global impression (cgi) scale. |
1997-04-29 |
2023-08-12 |
Not clear |
| J De Vry, J Fritze, R M Pos. The management of coexisting depression in patients with dementia: potential of calcium channel antagonists. Clinical neuropharmacology. vol 20. issue 1. 1997-04-28. PMID:9037570. |
depression in patients with dementia is currently treated with a variety of standard antidepressive agents (tricyclic antidepressants, selective serotonin reuptake inhibitors, monoamine oxidase inhibitors), but none is free from significant side effects. |
1997-04-28 |
2023-08-12 |
Not clear |
| A V Ravindran, R Judge, B N Hunter, J Bray, N H Morto. A double-blind, multicenter study in primary care comparing paroxetine and clomipramine in patients with depression and associated anxiety. Paroxetine Study Group. The Journal of clinical psychiatry. vol 58. issue 3. 1997-04-28. PMID:9108813. |
the serotonin selective reuptake inhibitors have demonstrated efficacy in the treatment of both depression and certain anxiety states. |
1997-04-28 |
2023-08-12 |
Not clear |
| K A Smith, C G Fairburn, P J Cowe. Relapse of depression after rapid depletion of tryptophan. Lancet (London, England). vol 349. issue 9056. 1997-04-25. PMID:9093253. |
however, there is no direct evidence that lowered serotonin function causes major depression. |
1997-04-25 |
2023-08-12 |
Not clear |
| C A Stockmeier, G E Dilley, L A Shapiro, J C Overholser, P A Thompson, H Y Meltze. Serotonin receptors in suicide victims with major depression. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 16. issue 2. 1997-04-15. PMID:9015799. |
serotonin receptors in suicide victims with major depression. |
1997-04-15 |
2023-08-12 |
human |
| I Karlsso. Treatment of non-cognitive symptoms in dementia. Acta neurologica Scandinavica. Supplementum. vol 168. 1997-04-09. PMID:8997427. |
specific serotonin re-uptake inhibitors (ssri) are efficient in the treatment of both depression and anxiety while tricyclic antidepressants have side effects including cognitive reduction. |
1997-04-09 |
2023-08-12 |
Not clear |
| S B Park, D J Williamson, P J Cowe. 5-HT neuroendocrine function in major depression: prolactin and cortisol responses to D-fenfluramine. Psychological medicine. vol 26. issue 6. 1997-04-08. PMID:8931165. |
5-ht neuroendocrine function in major depression: prolactin and cortisol responses to d-fenfluramine. |
1997-04-08 |
2023-08-12 |
Not clear |
| M Maes, E Vandoolaeghe, R Desnyde. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. Journal of affective disorders. vol 41. issue 3. 1997-04-02. PMID:8988452. |
fluoxetine, a selective serotonin (5-ht) reuptake inhibitor (ssri), and trazodone, a heterocyclic antidepressant, are effective in the treatment of major depression and treatment resistant depression (trd). |
1997-04-02 |
2023-08-12 |
Not clear |
| M Maes, E Vandoolaeghe, R Desnyde. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression. Journal of affective disorders. vol 41. issue 3. 1997-04-02. PMID:8988452. |
it has been shown that pindolol, a serotonin (5-ht)1a-receptor antagonist, may shorten the latency of onset of ssris in depression. |
1997-04-02 |
2023-08-12 |
Not clear |
| T A Slotkin, E C McCook, J C Ritchie, B J Carroll, F J Seidle. Serotonin transporter expression in rat brain regions and blood platelets: aging and glucocorticoid effects. Biological psychiatry. vol 41. issue 2. 1997-04-02. PMID:9018387. |
the results suggest that there are basic biologic differences in the effects of glucocorticoids in aged vs. young brain that could contribute to lowered effectiveness to antidepressants in elderly depression; if transport capacity is already reduced by the effects of increased glucocorticoids, further inhibition of transport by antidepressants would have proportionally less impact on synaptic serotonin concentrations. |
1997-04-02 |
2023-08-12 |
rat |
| D Bakish, P Cavazzoni, J Chudzik, A Ravindran, P D Hrdin. Effects of selective serotonin reuptake inhibitors on platelet serotonin parameters in major depressive disorder. Biological psychiatry. vol 41. issue 2. 1997-04-02. PMID:9018388. |
the effects of treatment with serotonin (5-ht) reuptake inhibitors on platelet 5-ht2 receptors, 5-ht reuptake sites an 5-ht uptake were studied in a double-blind trial comparing two selective serotonin reuptake inhibitors (ssri), paroxetine, and fluoxetine, for the treatment of major depression. |
1997-04-02 |
2023-08-12 |
Not clear |
| D Bakish, P Cavazzoni, J Chudzik, A Ravindran, P D Hrdin. Effects of selective serotonin reuptake inhibitors on platelet serotonin parameters in major depressive disorder. Biological psychiatry. vol 41. issue 2. 1997-04-02. PMID:9018388. |
hamilton depression rating scale (ham-d) scores and platelet 5-ht parameters were determined in 21 depressed patients at baseline, after 4 and 8 weeks of treatment, and were compared to 21 healthy controls. |
1997-04-02 |
2023-08-12 |
Not clear |
| A Reipschläger, G E Nilsson, H O Pörtne. A role for adenosine in metabolic depression in the marine invertebrate Sipunculus nudus. The American journal of physiology. vol 272. issue 1 Pt 2. 1997-03-31. PMID:9039028. |
among amino acids (gamma-aminobutyric acid, glutamate, glycine, taurine, serine, and aspartate) and monoamines (serotonin, dopamine, and norepinephrine), some changes were significant, but none were consistent with metabolic depression under all experimental conditions applied. |
1997-03-31 |
2023-08-12 |
Not clear |
| G M Brow. Reduced serotonin responsivity in depression. The American journal of psychiatry. vol 154. issue 3. 1997-03-26. PMID:9054808. |
reduced serotonin responsivity in depression. |
1997-03-26 |
2023-08-12 |
Not clear |
| J E Menting, A Honig, F R Verhey, M Hartmans, N Rozendaal, H C de Vet, H M van Praa. Selective serotonin reuptake inhibitors (SSRIs) in the treatment of elderly depressed patients: a qualitative analysis of the literature on their efficacy and side-effects. International clinical psychopharmacology. vol 11. issue 3. 1997-03-19. PMID:8923095. |
a qualitative analysis of studies on the efficacy and side-effects of selective serotonin reuptake inhibitors (ssris) for the treatment of elderly people with depression is presented. |
1997-03-19 |
2023-08-12 |
Not clear |
| Y Lecrubier, Y Pletan, A Solles, A Tournoux, V Magn. Clinical efficacy of milnacipran: placebo-controlled trials. International clinical psychopharmacology. vol 11 Suppl 4. 1997-03-19. PMID:8923124. |
the clinical efficacy of milnacipran, a selective serotonin and noradrenaline reuptake inhibitor, was reviewed on the basis of three, multicentre, placebo-controlled trials in major depression. |
1997-03-19 |
2023-08-12 |
Not clear |
| J Lopez-Ibor, J D Guelfi, Y Pletan, A Tournoux, J F Pros. Milnacipran and selective serotonin reuptake inhibitors in major depression. International clinical psychopharmacology. vol 11 Suppl 4. 1997-03-19. PMID:8923126. |
milnacipran and selective serotonin reuptake inhibitors in major depression. |
1997-03-19 |
2023-08-12 |
Not clear |
| J Lopez-Ibor, J D Guelfi, Y Pletan, A Tournoux, J F Pros. Milnacipran and selective serotonin reuptake inhibitors in major depression. International clinical psychopharmacology. vol 11 Suppl 4. 1997-03-19. PMID:8923126. |
selectivity for the single neurotransmitter, serotonin, may explain why ssris tend to be less efficacious than the tcas, especially in more serious forms of depression. |
1997-03-19 |
2023-08-12 |
Not clear |